Loading…
Sectoral / Thematic · quant Mutual Fund · AMFI code 151853quant Healthcare Fund
Disclosed for 38 months, Aug 2023 to Sep 2026.
Portfolio value
₹428 Cr
up ₹31.1 Cr vs Jul 2026
- Stocks held
- 11
- down 1 vs Jul 2026
- Top 10 weight
- 83.9%
- of the portfolio in its ten largest
quant Healthcare Fund is an active equity fund in the Sectoral / Thematic category from quant Mutual Fund. In August 2026 it disclosed 11 stocks worth ₹428 Cr, up ₹31.1 Cr from Jul 2026. Its largest positions were GlaxoSmithKline Pharmaceuticals Limited (10.6%), Glenmark Pharmaceuticals Ltd 29/09/2026 (9.8%), Divi's Laboratories Limited 29/09/2026 (9.5%); the ten largest together made up 83.9% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 88.1% of its equity. Cash and debt stood at 1.0%. Compared with Jul 2026 the fund entered 1 new stock and exited 2.
Against 229 other Sectoral / Thematic funds
Concentration
98%
Top-10 weight is higher than 98% of peers
Breadth
0%
Holds more stocks than 0% of peers
Cash
11%
Holds more cash than 11% of peers
What these mean: concentration · cash
Holdings in August 2026
Download CSVEvery line the fund disclosed, with the change against Jul 2026. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| GlaxoSmithKline Pharmaceuticals Limited | 10.58% | up 0.65 pts | ₹45.3 Cr | up ₹5.9 Cr | Added |
| Glenmark Pharmaceuticals Ltd 29/09/2026 Derivative | 9.83% | up 9.83 pts | ₹42.1 Cr | up ₹42.1 Cr | New |
| Divi's Laboratories Limited 29/09/2026 Derivative | 9.46% | up 9.46 pts | ₹40.5 Cr | up ₹40.5 Cr | New |
| Zydus Lifesciences Limited | 9.30% | up 9.30 pts | ₹39.8 Cr | up ₹39.8 Cr | New |
| Pfizer Limited | 8.83% | up 3.00 pts | ₹37.8 Cr | up ₹14.7 Cr | Added |
| Glenmark Life Sciences Limited | 8.08% | up 0.89 pts | ₹34.6 Cr | up ₹6.1 Cr | Added |
| Torrent Pharmaceuticals Ltd 29/09/2026 Derivative | 7.87% | up 7.87 pts | ₹33.7 Cr | up ₹33.7 Cr | New |
| Concord Biotech Limited | 7.03% | down 2.62 pts | ₹30.1 Cr | down ₹8.2 Cr | Trimmed |
| SMS Pharmaceuticals Limited | 6.71% | down 0.57 pts | ₹28.7 Cr | down ₹16 L | Trimmed |
| IPCA Laboratories Limited | 6.22% | up 0.28 pts | ₹26.6 Cr | up ₹3.1 Cr | Added |
| Zydus Wellness Limited | 5.64% | down 3.69 pts | ₹24.2 Cr | down ₹12.9 Cr | Trimmed |
| Aurobindo Pharma Limited | 5.18% | up 0.04 pts | ₹22.2 Cr | up ₹1.8 Cr | Added |
| Strides Pharma Science Limited | 2.45% | down 0.19 pts | ₹10.5 Cr | — | Held |
| Aurobindo Pharma Limited 29/09/2026 Derivative | 1.50% | up 1.50 pts | ₹6.4 Cr | up ₹6.4 Cr | New |
| 91 Days Treasury Bill 03-Sep-2026 Debt | 0.70% | down 0.05 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 10-Sep-2026 Debt | 0.70% | down 0.05 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 17-Sep-2026 Debt | 0.70% | down 0.05 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 15-Oct-2026 Debt | 0.70% | down 0.05 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 22-Oct-2026 Debt | 0.70% | down 0.05 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 05-Nov-2026 Debt | 0.69% | up 0.69 pts | ₹3 Cr | up ₹3 Cr | New |
| 91 Days Treasury Bill 19-Nov-2026 Debt | 0.69% | up 0.69 pts | ₹3 Cr | up ₹3 Cr | New |
| 91 Days Treasury Bill 27-Nov-2026 Debt | 0.69% | up 0.69 pts | ₹3 Cr | up ₹3 Cr | New |
| Sumitomo Chemical India Limited | 0.31% | down 0.02 pts | ₹1.3 Cr | up ₹2 L | Added |
| Cash, TREPS & receivables | −4.55% | up 1.75 pts | −₹19.5 Cr | up ₹5.5 Cr | Added |
What changed, Jul 2026 to Aug 2026
New New positions (1)
- Zydus Lifesciences Limited9.3% · ₹39.8 Cr
Exited Exited (2)
- Aster DM Healthcare Limitedwas 9.2% · ₹36.7 Cr
- HFCL Limitedwas 7.9% · ₹31.3 Cr
Added Biggest additions
- Pfizer Limitedup ₹14.7 Cr (+3.00% pts)
- Glenmark Life Sciences Limitedup ₹6.1 Cr (+0.89% pts)
- GlaxoSmithKline Pharmaceuticals Limited ₹5.9 Cr (+0.65% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jul 2026, the weight rose most in Pharmaceuticals & Biotechnology (+24.7 pts) and Pharmaceuticals (+0.2 pts), and fell most in Healthcare Services (−11.5 pts) and Telecom - Services (−9.8 pts).
- Pharmaceuticals & Biotechnology63.4% → 88.1%+24.7 pts
- Pharmaceuticals3.3% → 3.5%+0.2 pts
- Healthcare Services11.5% → 0.0%exited−11.5 pts
- Telecom - Services9.8% → 0.0%exited−9.8 pts
- Food Products11.6% → 8.0%−3.6 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Aug 2023 | Aug 2025 | Feb 2026 | May 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 50.2% | 65.8% | 64.0% | 52.0% | 63.4% | 88.1% |
| Food Products | — | 7.8% | 8.5% | 12.6% | 11.6% | 8.0% |
| Pharmaceuticals | — | — | — | 3.8% | 3.3% | 3.5% |
| Fertilizers & Agrochemicals | — | — | — | — | 0.4% | 0.4% |
Allocation in Aug 2026change vs Jul 2026
- Pharmaceuticals & Biotechnology (8)88.1%▲ 24.7 pts
- Food Products (1)8.0%▼ 3.6 pts
- Pharmaceuticals (1)3.5%▲ 0.2 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Aug 2026
1.0%
▲ 0.6 pts vs Jul 2026
- Cash alone
- −4.5%
- cash and net receivables
- A year earlier
- 1.4%
- Aug 2025 · now ▼ 0.4 pts
- Last 12 months
- 0.1% – 11.0%
- lowest to highest · record 11.0% in Apr 2026
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.